Axsome starts Ph III of AXS-05 to treat agitation in AD patients

Axsome Therapeutics Inc. (NASDAQ:AXSM) began the Phase II/III ADVANCE-1 trial of AXS-05 to treat agitation in patients with Alzheimer's disease. The double-blind, U.S. trial will enroll about 435 patients to receive placebo, bupropion or oral AXS-05 for 5 weeks. The primary endpoint is change from baseline to week 5 in the Cohen-Mansfield Agitation Inventory (CMAI)...